Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial

Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial

Summary: Group B streptococcus (GBS) is a leading cause of life-threatening neonatal infections and subsets of adverse pregnancy outcomes. Essentially all GBS strains possess one allele of the alpha-like protein (Alp) family. A maternal GBS vaccine, consisting of the fused N-terminal domains of the...

Full description

Bibliographic Details
Main Authors: Majela Gonzalez-Miro, Andrzej Pawlowski, Janne Lehtonen, Duojia Cao, Sara Larsson, Michael Darsley, Geoff Kitson, Per B. Fischer, Bengt Johansson-Lindbom
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:iScience
Subjects:
Immunology
Microbiology
Bacteriology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004223003383

Internet

http://www.sciencedirect.com/science/article/pii/S2589004223003383

Similar Items